Introduction {#s02}
============

The innate lymphoid cell (ILC) family consists of a variety of innate immune cells that lack antigen specificity, are enriched at mucosal and barrier surfaces, and regulate immune responses and tissue homeostasis ([@bib98]; [@bib164]; [@bib162]; [@bib174]; [@bib36]; [@bib96]; [@bib4]). Classical NK cells were the first ILCs identified, and they promote protective immune responses against pathogens and tumor cells ([@bib174]). Lymphoid tissue inducer (LTi) cells that orchestrate the formation of secondary lymphoid tissues were subsequently identified and later classified as members of the ILC family ([@bib98]). More recently, groundbreaking work in murine models and numerous studies of human tissue samples has expanded the family to include the group 1, 2, and 3 ILC subsets (ILC1s, ILC2s, and ILC3s, respectively), which are defined by the cytokines and transcription factors they express and their effector functions ([@bib162]). These cells produce cytokines, integrate environmental signals, and interact with other immune cells to regulate immunity, inflammation, and tissue homeostasis ([@bib36]; [@bib96]; [@bib4]). Although all ILCs arise from a common precursor early in development, elegant studies have revealed that classical NK cell development branches off and is distinct from that of other ILC subsets and that classical NK cells perform unique functions compared with other ILCs ([@bib174]). Therefore, this review solely focuses on the noncytolytic, "helper-like" ILCs.

Noncytolytic ILCs arise from a common lymphoid progenitor found in the bone marrow ([@bib36]; [@bib4]). The development of these cells either requires or involves the γ chain (γ~c~) cytokine IL-7; the transcription factors inhibitor of DNA binding 2 (Id2; [@bib43]; [@bib111]; [@bib147]; [@bib25]; [@bib81]), GATA-binding protein 3 (GATA3; [@bib156]; [@bib183]), promyelocytic leukemia zinc finger protein (PLZF; [@bib28]), nuclear factor interleukin-3 regulated (Nfil3; [@bib50]; [@bib155]), T cell factor-1 (TCF1; [@bib101]; [@bib185]), and thymocyte selection--associated high-mobility group box (TOX; [@bib154]); and Flt3 ligand ([@bib7]). ILCs populate lymphoid organs but are particularly enriched at mucosal and barrier surfaces and are rapid and potent cytokine producers that participate in a variety of immune responses ([@bib36]; [@bib96]; [@bib4]). Indeed, the noncytolytic, helper-like ILC1s, ILC2s, and ILC3s parallel the major CD4^+^ Th type 1, 2, and 17 (Th1, Th2, and Th17) subsets and express similar transcription factors and cytokines ([@bib162]; [@bib135]). ILC1s express the transcription factor T-box expressed in T cells (T-bet) and produce IFN-γ, making them key contributors to cell-mediated immune responses to bacteria and protozoan parasites ([@bib152]; [@bib11]; [@bib47]; [@bib81]). ILC2s express GATA3, type 2 cytokines such as IL-4, IL-5, IL-9, and IL-13, the growth factor amphiregulin (Areg), and met-enkephalin peptides to promote type 2 immune responses that protect against helminth infection, cause allergic inflammation, mediate tissue repair, and maintain metabolic homeostasis ([@bib111]; [@bib117]; [@bib129]; [@bib108]; [@bib75]; [@bib120]; [@bib36]; [@bib96]; [@bib4]; [@bib16]). Finally, ILC3s express retinoid-related orphan receptor γt (RORγt) and produce IL-17A, IL-22, and lymphotoxin ([@bib99]; [@bib146]; [@bib149]; [@bib159], [@bib160]; [@bib96]). ILC3s are the most heterogeneous ILC population and can be divided into three main groups: LTi cells and LTi-like C-C chemokine receptor type 6 (CCR6)--expressing ILC3s that contribute to the development of lymphoid structures and intestinal inflammation and the T-bet^+^ natural cytotoxicity receptor NCR^+^ and NCR^−^ ILC3s that promote tissue homeostasis, antibacterial immunity, and autoimmune inflammation ([Fig. 1](#fig1){ref-type="fig"}, inset; [@bib99]; [@bib146]; [@bib149]; [@bib159], [@bib160]; [@bib80]; [@bib131]; [@bib96]).

![**ILC3s promote GALT formation, inflammation, immunity, and homeostasis in the intestine.** A progenitor that expresses multiple transcription factors, including PLZF and Id2, responds to IL-7 and differentiates into RORγt-expressing ILC3s (though notably CCR6-expressing/LTi cell progenitors do not express PLZF). Mature ILC3s then integrate multiple environmental cues that modulate their effector functions. These cells are activated by IL-23 produced by myeloid cells through expression of the IL-23R. They can also respond to signals from the microbiota and dietary factors, such as AhR ligands and vitamins. Together, these signals regulate the ability of ILC3s to produce cytokines such as lymphotoxin, IL-17, and IL-22. Three major ILC3 subsets exist, including the CCR6^+^NCR^−^T-bet^−^ LTi and LTi-like cells, the CCR6^−^NCR^−^T-bet^+^ ILC3s, and the CCR6^−^NCR^+^T-bet^+^ ILC3s. ILC3-derived cytokines then promote GALT formation (LTi cells), regulate intestinal homeostasis and inflammation during IBD and in other contexts (CCR6^−^NCR^+/−^T-bet^+^ ILC3s), and contribute to protective immunity to intestinal pathogens (CCR6^−^NCR^+/−^T-bet^+^ ILC3s). Finally, LTi-like ILC3s express MHC class II, which allows them to interact with and delete commensal-specific CD4^+^ T cells to maintain tolerance of commensal bacterial species and intestinal homeostasis.](JEM_20160525_Fig1){#fig1}

Despite the parallels between ILC and Th subsets, ILCs lack expression of antigen-specific receptors and do not directly mediate antigen-specific responses ([@bib36]; [@bib96]; [@bib4]). Instead, ILCs coordinate signals from the epithelium, the microbiota, pathogens, and other immune cells by expressing an array of cytokine and eicosanoid receptors and cytokines, thus acting as central organizers of immune responses ([@bib41]; [@bib122]; [@bib75]; [@bib36]; [@bib96]; [@bib4]). The development of tools for ILC analysis has led to an explosion of studies unveiling new aspects of ILC development and function. This review will focus on recent work that highlights the unique abilities of ILCs to interact with their environment and other immune cells to orchestrate complex and diverse biological processes. In addition, we will highlight new challenges and questions that have emerged in the field. Finally, we will explore one of the major challenges in the study of ILCs: to develop therapies that selectively target ILC activities to treat human diseases.

ILC3s interact with the microbiota and innate and adaptive immune cells to regulate intestinal immune responses {#s03}
===============================================================================================================

LTi cells were the first non-NK cell members of the ILC family to be identified ([@bib99]; [@bib98]; [@bib122]). Later work characterized similar cells, including CCR6-expressing LTi-like ILC3s and NCR-expressing ILC3s, that participate in the formation of gut-associated lymphoid tissues (GALTs), including cryptopatches and isolated lymphoid follicles (ILFs), maintenance of intestinal homeostasis, and protection against infection ([Fig. 1](#fig1){ref-type="fig"}; [@bib36]; [@bib96]; [@bib4]). Recent studies have begun to unravel how ILC3s interface with the microbiota and various cell types to maintain intestinal function. New findings have led to questions related to how ILC3s are regulated throughout life, how they sense bacteria- and diet-derived factors to promote tolerance of commensal bacteria, and how they regulate intestinal immunity.

ILC3 hematopoiesis and lymphoid tissue formation {#s04}
------------------------------------------------

[@bib99] first described murine CD4^+^CD3^−^ LTi cells that promoted proper formation of secondary lymphoid tissues. A related LTi-like population was identified in the cryptopatches of mice ([@bib72]), and these cells were shown to interact with ILF B cells to promote IgA production ([@bib167]). In particular, expression of lymphotoxin by ILC3s is critical for their ability to support IgA production and lymphoid tissue development ([@bib167]; [@bib83]). Numerous studies have since described factors that regulate the development and function of these cells. Seminal studies from Littman and colleagues and others demonstrated that RORγt expression is required for the development of murine LTi cell and LTi-like ILC3s ([@bib43]; [@bib146]; [@bib144]; [@bib41]). These RORγt-expressing ILC3s were required for formation of cryptopatches, ILFs ([@bib42]; [@bib43]; [@bib79]; [@bib89]; [@bib85]) and Peyer's patches ([@bib8]) in mice. Importantly, RORγt is also expressed by human ILC3 progenitors ([@bib107]), and humans have LTi-like cells ([@bib31]), indicating that these cells and their functions are conserved in mice and humans. Other factors, including the aryl hydrocarbon receptor (AhR) and Notch ([@bib79]; [@bib128]; [@bib25]; [@bib85]; [@bib164]; [@bib131]), runt-related transcription factor 3 (Runx3; [@bib44]), and postnatal microbial colonization of the intestine, control the development and size of the murine LTi cell population ([@bib149]). In addition, recent work from [@bib70] showed that PLZF and TCF1 expression gradients control the committed development of LTi cells versus that of other ILC3s, suggesting that LTi cells are distinct from other ILC3s, though this remains to be fully elucidated, particularly in humans.

Together, these data identify a network of factors that influence ILC3 development and function. However, many questions remain. For example, whether ILC3 development requires the microbiota is controversial, as some studies have shown that ILC3s that express NKp46 were absent in germ-free mice ([@bib146]; [@bib144]), whereas other studies have demonstrated that this subset and/or other ILC3 subsets remained intact ([@bib144]; [@bib149], [@bib150]; [@bib133]; [@bib85]; [@bib160]). Notably, studies in murine models have shown that GALT formation is largely independent of the microbiota, with the exception of ILF formation ([@bib15]), but in contrast, maternal microbial colonization during gestation increases ILC3 population size in pups ([@bib181]), suggesting a complex relationship between ILC3 development, the microbiota, and GALT formation. In particular, how the microbiota affects the turnover and circulation of ILC3s and maintenance and organization of GALT in adults is unclear, though recent evidence suggests that specific species of commensal bacteria such as segmented filamentous bacteria can promote ILC3 production of IL-22 ([@bib5]) and IL-17 ([@bib143]) in adult mice. In addition, whether ILC3s orchestrate organization of tertiary lymphoid structures in tissues outside of the intestine in unknown. NCR-expressing ILC3s have been associated with the formation of tertiary lymphoid structures in the lung of humans with nonsmall cell lung cancer ([@bib19]), suggesting that diverse ILC3s in mice and humans might control lymphopoiesis throughout life in various tissues. Finally, although ILC-derived lymphotoxin supports communication between ILCs and T cells or DCs ([@bib30]; [@bib43]; [@bib41]; [@bib83]) and ILC interactions with stromal cells are also prominent ([@bib98]), the precise nature of the interactions between ILC3s and other cells that reside in the GALT is not fully defined. Thus, further studies will be required to understand how the pathways that regulate ILC3 development, function, and turnover shape GALT and tertiary lymphoid structure formation. As much of our understanding of these cells has been based on mechanistic studies in murine models, expanded analysis of human LTi cells will be required to fully appreciate the role of this population in humans throughout the lifespan.

ILC3s maintain the health of the superorganism {#s05}
----------------------------------------------

RORγt^+^ ILC3s in mice and humans support intestinal homeostasis by responding to IL-23, producing tissue-protective IL-17A, IL-17F, and IL-22, and interacting with various intestinal cell types and the microbiota ([Fig. 1](#fig1){ref-type="fig"}; [@bib41]; [@bib36]; [@bib96]; [@bib4]). In particular, the complex nature of the relationship between ILC3s and the intestinal microbiota has been a topic of great interest. Although there is controversy regarding whetherthe microbiota shapes development of ILC3s, microbial products have been shown to influence levels of intestinal IL-22, a tissue-protective cytokine made predominantly by RORγt-expressing ILC3s in both mice and humans that promotes production of antimicrobial peptides and mucins ([@bib158]; [@bib41]; [@bib36]; [@bib4]). How this process is regulated is also unclear, as murine ILC IL-22 production is not affected after alteration of commensal bacterial communities in some studies ([@bib160]), whereas other work showed that germ-free mice had decreased IL-22--expressing NKp46^+^ ILC3s ([@bib146]; [@bib144]; [@bib171]), and still other studies showed that the microbiota could repress murine ILC3-derived IL-22 through IL-25 production ([@bib191]; [@bib150]).

Although further work will be needed to understand whether the microbiota is required for IL-22 production by ILCs, particularly in humans, the microbiota clearly can affect ILC3 function and the return to homeostasis after inflammation and infection ([Fig. 1](#fig1){ref-type="fig"}). In response to intestinal damage and alterations in the microbiota caused by dextran sodium sulfate, murine ILC3s expanded and up-regulated IL-22, associated with a return to homeostasis ([@bib150]). Interestingly, specific commensal bacterial species appear to be able to differentially regulate ILC3 function, as segmented filamentous bacteria can promote IL-17 and IL-22 production from murine ILC3s ([@bib5]; [@bib143]). Notably, viruses can also modulate ILC3 activities ([@bib2]), as murine norovirus engaged TLR7 on DCs in mice, leading to IL-23 production, ILC3 expression of IL-22, and increased resistance to infection with vancomycin-resistant *Enterococcus faecium* in microbiota-depleted hosts ([@bib2]).

In addition to the role for the microbiota in shaping ILC3 responses, ILC3s in turn affect the composition and localization of commensal bacterial species. For example, IL-22--expressing LTi-like cells were critical for the anatomical containment of lymphoid-resident commensal *Alcaligenes*species and preventing systemic inflammation in mice ([@bib160]; [@bib48]). Importantly, antibody responses against *Alcaligenes* species were also associated with inflammatory bowel disease (IBD) in humans, suggesting that ILC3s may help to shape commensal microbial communities in both mice and humans ([@bib160]). In support of this idea, lymphoid tissue--resident commensal bacteria that reside within murine DCs in the GALT elicited IL-10 production that limited Th17 responses and promoted resistance to inflammation ([@bib48]).

Parallel to the role of ILC3s in maintaining a host-protective relationship with the microbiota, dysregulation of this relationship can be pathogenic, as IL-23 overexpression in mice was associated with inflammatory ILC3 responses that caused intestinal lesions that could be ameliorated with antibiotic treatment ([@bib24]). In addition, IL-17A-- and IFN-γ--expressing ILC3s promoted colitis in mice ([@bib17]), and ILC3-like cells that expressed IL-17 were associated with IBD in humans ([@bib52]). Thus, the relationship between ILC3s and the microbiota must be carefully regulated ([@bib36]; [@bib96]; [@bib4]). Of note, ILC3s have also been associated with inflammation outside of the intestine in both mice and particularly humans, such as the skin ([@bib75]; [@bib166]), and systemically during common variable immunodeficiency ([@bib27]), but the nature of the relationship between ILC3s and the microbiota in these tissues is unclear.

Numerous questions remain regarding the mechanisms by which ILC3s communicate with the microbiota and other environmental factors in the intestine and elsewhere. To begin to address this, recent studies have focused on how intestinal ILC3s sense dietary substances to regulate intestinal immunity ([Fig. 1](#fig1){ref-type="fig"}) and how ILC3s can also regulate intestinal homeostasis by influencing the "diet" of the microbiota. Vitamin A is sensed by murine ILC3s, and vitamin A deficiency was associated with impaired ILC3 responses ([@bib161]). In addition, maternal intake of retinoic acid regulated murine LTi cell responses and immune fitness in pups ([@bib169]), and retinoic acid caused murine ILC3s to up-regulate gut-homing receptors ([@bib77]). In addition, vitamin D deficiency was associated with altered commensal bacterial communities and increased ILC3 responses in mice ([@bib23]). Phytochemicals derived from cruciferous vegetables also stimulate the AhR and promote intestinal ILC3 activities in mice ([@bib79]), and cholesterol biosynthetic intermediates, ligands for RORγt, can regulate murine LTi cells ([@bib145]).

Parallel with their ability to react to host dietary compounds, ILC3s can also facilitate the transfer of fucose, which commensal bacteria use as a carbohydrate source, to the surface of murine intestinal epithelial cells. This process maintained an appropriate relationship between the intestinal epithelium and the microbiota, which was critical for resistance to infection with *Salmonella typhimurium* ([@bib57]). However, despite the connections between ILC3s, diet, and the microbiota, little is known regarding how ILC3s sense signals derived directly from the microbiota, as ILC3 responses are largely intact in mice that lack pattern recognition receptors, and ILC3s do not appear to express such receptors ([@bib149]). Because products derived from bacterial metabolism, such as short-chain fatty acids, indole, ethanolamine, alcohols, lactate, and others, can influence immune cell activities ([@bib91]), it is possible that ILC3s could respond to these metabolites, but this remains to be fully explored. Importantly, our understanding of how dietary and microbial products affect human ILC3 function in the intestine is very limited, and further studies in diverse populations of healthy humans and those with diseases associated with altered nutrient availability and microbial colonization are needed.

Finally, recent studies have explored how ILC3s and the microbiota affect the activities of other intestinal immune cells. In particular, interactions between ILC3s and myeloid cells are important. For example, the microbiota conditioned macrophages to produce IL-1β, which elicited ILC3 production of granulocyte-macrophage colony-stimulating factor that supported T regulatory cell (T reg cell) function in mice ([@bib113]). In addition, CX~3~CR1^+^ myeloid cells were shown to receive signals from the microbiota to up-regulate ILC3-derived IL-22 to protect against infection with the murine bacterial pathogen *Citrobacter rodentium* ([@bib90]). New studies have highlighted that ILC3s also shape adaptive immune responses in the intestine. Studies in mouse models by Sonnenberg and colleagues showed that MHC class II--expressing ILC3s interacted with and deleted CD4^+^ T cells specific for commensal antigens, demonstrating that ILC3s promote tolerance of the microbiota ([Fig. 1](#fig1){ref-type="fig"}; [@bib62], [@bib63]). Conversely, ILC3s isolated from the spleen of mice can also present antigens to elicit proinflammatory adaptive responses in the presence of adjuvants ([@bib172]). Thus, further studies using murine models of tolerance and inflammation, coupled with selective inhibition of pathways that ILC3s use to sense the microbiota in mice and associative studies in humans, will be needed to understand how NCR^−^ and NCR^+^ ILC3s interact with immune cells to maintain intestinal homeostasis and whether the activities of these cells could be targeted therapeutically to treat inflammatory diseases of the intestine.

ILC3s protect the host during infection and contribute to anticancer responses {#s06}
------------------------------------------------------------------------------

ILC3s also take center stage when the host is infected with microbial pathogens ([Fig. 1](#fig1){ref-type="fig"}; [@bib41]; [@bib36]; [@bib96]; [@bib4]). After intestinal infection in mice with the attaching and effacing bacterium *C. rodentium*, a protective role for ILC3-derived IL-22 was initially described ([@bib146]; [@bib193]; [@bib159]), and subsequent work showed that ILC3 expression of Runx3 played a key role in this process ([@bib44]). In the intestine, studies of murine models have shown that ILC3s interface with adaptive immune cells ([@bib177]), innate immune cells, and epithelial cells ([@bib53]) during infection. Myeloid cells associated with ILC3s through the CXCL16--CXCR6 pathway after *C. rodentium* infection of mice, which elicited ILC3-derived IL-22 and resistance to infection ([@bib148]), and in a virus-induced murine gastroenteritis model, IL-22--producing ILC3s were associated with protective IFN-λ responses ([@bib64]). In addition, expression of inhibitor of κB kinase α or β in intestinal epithelial cells was required for efficient production of IL-22 from ILC3s and protection from *C. rodentium* in mice ([@bib53]). Thus, IL-22--producing ILC3s are critical in mediating protective immune responses against intestinal pathogens ([Fig. 1](#fig1){ref-type="fig"}).

Importantly, recent work has shed light on how different ILC3 subsets contribute to intestinal homeostasis and resistance to bacterial pathogens. Studies from [@bib80] and [@bib131] described T-bet--expressing NCR^+^RORγt^+^ ILC3s that either promote resistance to or regulate homeostasis in response to bacterial infection in the intestine. CCR6^−^RORγt^+^ ILCs up-regulated T-bet in response to signals from IL-23 and the microbiota ([@bib80]), leading to Notch-directed NKp46 expression ([@bib80]; [@bib131]), consistent with a previous study ([@bib152]). Supporting a role for these cells during intestinal bacterial infection, T-bet--deficient mice had decreased NCR^+^RORγt^+^ ILC3s and were more susceptible to infection with *C. rodentium* ([@bib80]; [@bib131]). T-bet expression also enhanced IFN-γ production in NCR^+^RORγt^+^ ILC3s that promoted enterocolitis after *Salmonella enterica* infection, but in parallel directed the release of glycoproteins that protected the epithelial barrier ([@bib80]), demonstrating that these T-bet--expressing ILC3s can modulate the balance between host protection and intestinal homeostasis ([Fig. 1](#fig1){ref-type="fig"}). Interestingly, recent studies suggest that NCR^+^ ILC3s are not critically important for murine antibacterial immune responses in the presence of wild-type T cells ([@bib157]; [@bib132]), suggesting that effector functions may be compartmentalized in the ILC3 subsets or that redundancy exists to ensure that antibacterial immunity remains intact in the presence or absence of an effective T cell response. Notably, we know little regarding the role of ILC3s in protecting the human host during intestinal bacterial infection, though the recently described transcriptional heterogeneity of human ILC3s, as analyzed using single-cell RNA-sequencing ([@bib13]), suggests that compartmentalization of ILC3 effector function may also be conserved in humans.

ILC3s are also associated with protective immune responses in tissues other than the intestine ([@bib164]; [@bib36]; [@bib96]; [@bib4]). Experiments by [@bib6] showed that IL-22 mediated resistance to infection with *Klebsiella pneumoniae* in the murine lung, though the source of IL-22 in this study was presumed to be Th17 cells. A recent study has shown that cross-talk between monocytes and IL-17--producing ILC3s mediates innate immune defense against this antibiotic-resistant pathogen ([@bib1]). ILC3-like cells in the lung also mounted protective responses after vaccination with Bacillus Calmette--Guérin in mice ([@bib127]), and ILC3s accumulated in the murine lung and produced IL-22 after *Streptococcus pneumoniae* infection ([@bib170]). After infection with lymphocytic choriomeningitis virus in mice, IL-22--producing LTi-like cells helped to restore lymphoid architecture in secondary lymphoid tissues that were required for responses to secondary antigens ([@bib151]). Finally, in a murine model of oropharyngeal candidiasis, ILC3s in the oral mucosa produced IL-17A and IL-17F and were required for protective immunity ([@bib54]).

Finally, ILC3s can be tissue protective in contexts other than infection, particularly cancer and cancer treatment. For example, IL-22--producing LTi cells support thymic regeneration in mice after total-body irradiation ([@bib39]), and activated ILC3s in the peripheral blood of human leukemia patients that received a hematopoietic stem cell transplant were associated with reduced susceptibility to graft-versus-host disease ([@bib115]). Importantly, ILC3s can play a direct role in anticancer responses. ILC3s respond to IL-12 to promote leukocyte invasion of B16 melanoma tumors in mice ([@bib45]), and NCR-expressing ILC3s have been found in human small cell lung tumors and are correlated with the density of protective tertiary lymphoid structures ([@bib19]). In an oncogene-induced murine cancer model, non-NK, non--T innate lymphocytes expanded early after tumorigenesis and limited tumor growth, although these cells resembled ILC1s ([@bib32]). Evidence also exists that ILC3s can contribute to the development of cancer, as IL-22 produced by ILC3s can support the development of colorectal cancer in murine models, IL-23 overexpression was associated with ILC3 responses that drove intestinal adenoma formation ([@bib22]), and IL-22--producing CD3^−^ cells can be detected in human colorectal cancer ([@bib78]). Ultimately, extensive studies in murine models of cancer and in human cancer patients will be required to fully understand how ILC3s mediate tissue-protective responses and inflammation during cancer by interacting with the microbiota, the epithelium, and immune cells at multiple mucosal and barrier sites.

ILC2s at the nexus of inflammation, tissue repair, and homeostasis {#s07}
==================================================================

In 2010, three laboratories independently described a murine ILC population that drove type 2 immune responses ([@bib111]; [@bib117]; [@bib129]), and the next year two laboratories identified analogous populations in multiple fetal and adult human tissues ([@bib103]; [@bib108]). These cells, now referred to as ILC2s, promote protective immunity to helminth infection, allergic inflammation, tissue repair, and metabolic homeostasis ([@bib75]; [@bib36]; [@bib96]; [@bib4]). As has been the case with ILC3s, intensive interest in ILC2s has led to new challenges and questions in the field. In particular, questions remain regarding ILC2 development, how ILC2s interact with epithelial and immune cells, and how they balance their abilities to maintain homeostasis, promote repair, and cause inflammation.

A regulatory network governs ILC2 development and function {#s08}
----------------------------------------------------------

Recent work has shown that ILC2 development and function depends on a complex network of pathways. Specific transcription factors, such as RORα ([@bib59]; [@bib179]), TCF1 ([@bib184]), growth factor independent 1 transcription repressor (Gfi1; [@bib163]), and B cell CLL/lymphoma 11b (Bcl11b; [@bib176]; [@bib189]), contribute to murine ILC2 development. Some of these factors are also critical for ILC2 effector functions, as continuing expression of GATA3 in mature ILC2s is needed for normal murine ILC2 function ([@bib66]), and loss of Bcl11b expression results in loss of ILC2 gene expression and function and acquisition of ILC3-like properties in mice ([@bib18]).

After development, cytokines derived from epithelial cells, including IL-25, IL-33, and thymic stromal lymphopoietin (TSLP), and immune cell--derived γ~c~ cytokines, such as IL-2, IL-4, and IL-7, promote murine and human ILC2 survival and activation ([@bib111]; [@bib117]; [@bib129]; [@bib75], [@bib76]; [@bib36]; [@bib96]; [@bib114]; [@bib121]; [@bib4]; [@bib137]). IL-2 derived from T cells ([@bib121]) or other ILCs ([@bib137]) is particularly important. Additional proteins that influence murine ILC2s include IL-9 ([@bib168]; [@bib104]), the TNF family member tumor necrosis factor--like ligand 1A ([@bib100]; [@bib188]), and the receptor for advanced glycation end products, an immunoglobulin superfamily molecule produced by nonhematopoietic cells in the lung ([@bib119]). Interestingly, new work has shown that human ILC2s can also respond to IL-12 signaling to up-regulate IFN-γ and T-bet expression, indicating that human ILC2s have the ability to respond to a diverse set of environmental signals ([@bib88]).

Recent work has also highlighted a role for nonprotein factors, including bioactive lipids such as eicosanoids, in regulating ILC2 functions. [@bib103] initially identified human ILC2s by expression of the prostaglandin D~2~ (PGD~2~) receptor chemoattractant receptor--homologous molecule expressed on Th2 cells (CRTH2). Indeed, many of the studies describing the effect of PGD~2~ on ILC2s have been in humans, establishing a role for the PGD~2~--CRTH2 pathway in mediating human ILC2 chemotaxis, cytokine production, and possibly accumulation in the lung ([@bib9]; [@bib182]; [@bib165]), with increases in CRTH2^+^ ILC2s observed in the peripheral blood of allergic asthma patients ([@bib10]) and esophageal tissues of patients with the allergic disease eosinophilic esophagitis ([@bib38]). Murine and human ILC2s respond to other eicosanoids, including leukotriene D~4~, which enhanced their function ([@bib37]), lipoxin A~4~ (LXA~4~), which limited their activation ([@bib9]), and PGI~2~, which inhibited IL-33--elicited IL-5 and IL-13 production in mice ([@bib194]). Interestingly, little is currently known about how ILC2s interact with mast cells and basophils that produce eicosanoids, though TSLP-responsive ILCs in the inflamed skin of mice and humans interact with both cell types ([@bib136]; [@bib76]) and IL-4 derived from basophils supported ILC2 responses in a murine model of allergen-induced airway eosinophilia ([@bib114]). This work suggests that cytokine and bioactive lipid pathways converge to regulate ILC2 responses, but further studies will be required to reveal how the interplay of transcription factors, cytokines, and bioactive lipids coordinate murine and human ILC2 activities.

ILC2s interact with the epithelium and immune cells to promote type 2 inflammation {#s09}
----------------------------------------------------------------------------------

ILC2s were formally first identified in murine fat-associated lymphoid clusters and during infection with the rodent nematode parasite *Nippostrongylus brasiliensis* ([@bib111]; [@bib117]; [@bib129]). Based on observations that adaptive cells could not fully account for type 2 cytokine production required for helminth expulsion using mouse models of infection ([@bib46]), seminal studies revealed that innate cells, later designated ILC2s, were the predominant source of IL-13 after *N. brasiliensis* infection that was required for changes in the intestinal epithelium that lead to parasite expulsion ([Fig. 2](#fig2){ref-type="fig"}; [@bib111]; [@bib117]; [@bib129]). These studies have been extended to show that ILC2s also promote immune responses to *Strongyloides venezuelensis* in mice ([@bib187]), suggesting that these cells are key mediators of murine antihelminth responses against multiple species. Of note, how these cells contribute to human resistance to helminth parasites remains uncertain. A recent study has shown that children infected with *Schistosoma haematobium* had decreased peripheral blood ILC2s ([@bib116]), suggesting that ILC2s may depopulate the blood and accumulate in tissues in helminth-infected individuals. However, more studies are needed to determine whether ILC2s are as critical for helminth resistance in humans as they are in mice.

![**ILC2s influence inflammation, immunity, tissue repair, and homeostasis through interactions with hematopoietic and nonhematopoietic cells.** ILC2s that express GATA3 differentiate from a progenitor cell that expresses a variety of transcription factors, including PLZF and Id2. These progenitors respond to IL-7 and other factors as they differentiate. Once mature, ILC2s sense multiple signals, including cytokines that can be derived from the epithelium, including IL-25, IL-33, and TSLP, and mast cell--derived eicosanoids such as PGD~2~ and others. Activated ILC2s produce type 2 cytokines, including IL-4, IL-5, IL-9, and IL-13. During *N. brasiliensis* infection, these cytokines are protective and elicit mucin production that induces helminth expulsion. These cytokines can also cause type 2 inflammation associated with allergic disease in multiple tissues. IL-9 feeds back in an autocrine loop to promote ILC2 survival during inflammation, and IL-4 produced by basophils also supports ILC2 population expansion (not depicted). The proinflammatory effects of ILC2s are balanced by their ability to promote homeostasis and tissue repair. In this context, type 2 cytokines derived from ILC2s support wound healing and maintain eosinophil (Eos) and alternatively activated macrophage (AAM) populations in adipose tissue, which, together with ILC2-derived met-enkephalin peptides, promote and support the lean state. Finally, activated ILC2s can produce growth factors that directly act on the epithelium to repair damaged tissues.](JEM_20160525_Fig2){#fig2}

The latest work has again used murine models to dissect how interactions between ILC2s and other cell types coordinate antihelminth responses. Cytokines produced by epithelial cells, such as IL-25 and IL-33, elicit distinct populations of innate cells that contribute to antihelminth immunity in murine models ([@bib139], [@bib140]; [@bib68]). Additionally, a recent study demonstrated that IL-25 drove the emergence of inflammatory ILC2s that expressed killer cell lectin-like receptor G1 (KLRG1), differentiated into classical ILC2s, and supported *N. brasiliensis* expulsion from the murine intestine ([@bib68]). Interestingly, these inflammatory ILC2s could also produce IL-17 ([@bib163]; [@bib68]) and provided protection against *Candida albicans* ([@bib68]), suggesting that murine inflammatory ILC2s can combat an array of pathogens. New studies have identified the Tuft cell, a chemosensory intestinal epithelial cell type, as a primary source of IL-25 in the context of parasite infection in mice ([@bib51]; [@bib65]; [@bib173]). In addition to their relationship with epithelial cells, ILC2s also maintain a dialogue with adaptive CD4^+^ T cells ([Fig. 2](#fig2){ref-type="fig"}). Studies by [@bib60], [@bib102], and [@bib121] together demonstrated that murine ILC2s express MHC II and interact with CD4^+^ T cells, supporting Th2 cell differentiation and ILC2 function during helminth infection or allergic disease, with a key role for CD4^+^ T cell--derived IL-2 in promoting ILC2 responses. In addition, IL-33 and T cell--derived IL-2 caused the ILC2 population to expand in the lung after rechallenge of mice with *N. brasiliensis* that led to parasite larval damage and prevention of reinfection ([@bib14]). Finally, recent work has shown that inducible T cell costimulator (ICOS)--ICOS ligand (ICOSL) interactions between ILC2s and T reg cells led to the development of helminth-associated T reg cell responses in mice ([@bib106]).

In addition to their role in helminth-induced type 2 inflammation, ILC2s drive allergic inflammatory diseases, including allergic airway inflammation in mice ([@bib58]; [@bib75]; [@bib96]; [@bib4]) and humans ([@bib10]; [@bib26]), and allergic inflammation in the skin and intestine ([@bib74],[@bib75]; [@bib136]; [@bib141]). As during helminth infection, pro-allergic ILC2 responses are regulated by interactions with various cell types ([Fig. 2](#fig2){ref-type="fig"}; [@bib9]; [@bib37]; [@bib75]; [@bib96]; [@bib4]; [@bib165]). Nonhematopoietic cells affect ILC2 responses, as structural airway cells that produce IL-33 and TSLP ([@bib104]) and pulmonary epithelial cells that produce transforming growth factor β ([@bib35]) shaped ILC2 responses in murine models of allergic airway inflammation. In similar models, nociceptor neurons in the lung responded to ILC2-derived IL-5 and the neuropeptide vasoactive intestinal peptide to promote allergic inflammation ([@bib49]). In addition, interactions between human ILC2s that express NKp30 and keratinocytes that express the activating ligand B7-H6 may promote atopic dermatitis ([@bib142]).

ILC2s also have a complex communication network with other hematopoietic cells in the context of allergic disease. Interactions between ILC2s and CD4^+^ T cells drive allergic inflammation ([@bib58]; [@bib75]; [@bib96]; [@bib4]), and ILCs also interact closely with other innate cells. For example, interactions among ILC2s ([@bib93]) and between ILCs and DCs ([@bib71]) mediated through the ICOS--ICOSL pathway drive allergic inflammation in the murine lung ([@bib107]; [@bib71]; [@bib93]). ILC2 interactions with mast cells ([@bib136]) and basophils ([@bib76]) are associated with atopic dermatitis--like disease in human and murine skin. Recent studies have highlighted an association between human ILC2s and eosinophils during chronic rhinosinusitis ([@bib103]; [@bib75]; [@bib175]) and eosinophilic esophagitis ([@bib38]). Finally, type 1 IFN and IL-27 produced by innate cells antagonize ILC2 function to limit allergic lung inflammation ([@bib40]; [@bib95]; [@bib112]). Together, these data show that ILC2s communicate with nonhematopoietic and hematopoietic cell types to mediate allergic inflammation, suggesting that these interactions might be targeted to treat ILC2-associated allergic diseases in humans.

Thus, interactions between ILC2s, the epithelium, and other immune cells mediate protective immunity to helminth parasites and allergic inflammation ([Fig. 2](#fig2){ref-type="fig"}), but numerous questions remain. Future studies will require the use of sophisticated genetic and imaging tools in murine models of helminth infection and allergy to better understand the molecular mechanisms by which ILC2s interface with the epithelium, other hematopoietic cells, and the microbiota and how ILC2 responses are turned off. An additional challenge is to determine how ILC2s function during human parasitic infection and allergic disease and how these cells regulate the balance between these distinct type 2 inflammatory states. The finding that human *S. haematobium* infection was associated with a decrease in ILC2s in the peripheral blood ([@bib116]) could suggest that *S. haematobium* actively modulates human ILC2 responses. Consistent with this idea, in murine models, *Heligmosomoides polygyrus* elicited IL-1β that decreased IL-25 and IL-33 levels to support chronicity of infection ([@bib190]), and products of *H. polygyrus* could limit ILC2 responses and allergic lung inflammation ([@bib97]). These findings provoke the hypothesis that ILC2s influence the relationship between helminth infection and allergy, and future studies investigating ILC2 regulation, particularly in helminth-infected and allergic humans, should provide new insight into how these cells balance protective and pathological inflammation in multiple tissues.

ILC2s limit inflammation and promote tissue homeostasis {#s10}
-------------------------------------------------------

In addition to their inflammatory properties, ILC2s play diverse roles in limiting inflammation, regulating tissue repair, and maintaining homeostasis ([Fig. 2](#fig2){ref-type="fig"}; [@bib36]; [@bib96]; [@bib4]). One mechanism through which this occurs is via production of type 2 cytokines, which can regulate type 1 or type 17 inflammation ([@bib96]; [@bib4]). Decreased numbers of type 2 cytokine--expressing ILC2s were associated with experimental murine autoimmune encephalitis ([@bib138]), and type 2 cytokine--expressing ILC2s supported tissue protection in a murine model of renal reperfusion injury ([@bib67]) and biliary atresia ([@bib87]). In addition, cigarette smoke altered IL-33 responsiveness in the murine lung to limit ILC2 production of type 2 cytokines, associated with susceptibility to viral infection ([@bib73]). Importantly, the ability of ILC2s to participate in tissue repair through type 2 cytokine production can become dysregulated, as pulmonary fibrosis in mice after *Schistosoma mansoni* infection or Bleomycin administration ([@bib61]) and liver fibrosis ([@bib94]) was dependent on IL-13--producing ILC2s. Thus, further studies will be required to determine how ILC2s can repair tissues without contributing to fibrosis, particularly in humans.

ILC2s also express factors that directly lead to wound healing, such as the growth factor Areg, which was critical in mediating repair of the damaged respiratory and intestinal epithelium after murine influenza A virus infection and intestinal injury and inflammation, respectively ([@bib108], [@bib109]). Areg-producing ILC2s that responded to IL-9 have also been associated with lung tissue repair after helminth infection in mice ([@bib168]), and IL-33--responsive ILC2s promote cutaneous wound healing in mice and are associated with acute wounds in human skin ([@bib130]). These data suggest that ILC2s contribute to tissue repair using multiple mechanisms, and future studies may reveal that these cells produce additional growth factors associated with tissue repair.

Studies in murine models have also shown that ILC2s can interact with other regulatory cells, such as T reg cells, to suppress inflammation and promote healing. For example, ILC2 responses led to the accumulation of T reg cells and alternatively activated macrophages that protected against cerebral malaria in mice ([@bib12]). Interactions between T reg cells and ILC2s via maresin 1, a docosahexaenoic acid--derived lipid mediator, were also associated with resolution of murine allergic lung inflammation ([@bib82]). A recent study showed that IL-33--driven ILC2 activation was required for ICOS--ICOSL-mediated interactions with between ILC2s and T reg cells during helminth infection ([@bib106]). Together, these data suggest that key interactions between T reg cells and ILC2s lead to resolution of inflammation, but further studies will be needed to assess the molecular mechanisms by which T reg cells and ILC2s colocalize and interact and whether these interactions are conserved in humans.

The capacity of ILC2s to suppress inflammation and support tissue repair is complemented by the part they play in maintaining tissue homeostasis, particularly metabolic homeostasis ([Fig. 2](#fig2){ref-type="fig"}). Type 1 inflammation is associated with metabolic disorders and obesity, whereas type 2 cytokines underpin metabolic health, optimized caloric expenditure, and a healthy weight ([@bib180]; [@bib120]). Initial work showed that IL-33--responsive, IL-5--producing ILC2s maintained adipose eosinophil and macrophage populations associated with leanness in mice ([@bib105]). Subsequent work has highlighted the importance of the IL-33--ILC2 axis specifically in the fat, as ILC2s were enriched in human and murine fat and IL-33--responsive ILC2 responses elicited beige adipocytes that expressed uncoupling protein 1, a key factor in regulating caloric expenditure and limiting adiposity, through expression of met-enkephalin peptides ([@bib16]; [@bib86]). Additionally, augmentation of murine ILC2 function by IL-25 and IL-33 treatment could promote weight loss, eosinophil accumulation in the fat, and improved glucose tolerance ([@bib16]), and this process was antagonized by proinflammatory IFN-γ responses ([@bib106]).

These studies suggest that ILC2s directly and indirectly interact with a variety of cell types in adipose tissue to support metabolic homeostasis. However, the factors that regulate these activities remain incompletely described. [@bib118] have shown that a neuropeptide regulated by caloric intake, vasoactive intestinal peptide, increased ILC2 production of IL-5, which enhances eosinophil responses associated with the lean state in mice. The ability of ILC2s to sense vitamin A deficiency also suggests that ILC2s can respond to dietary factors to participate in maintaining metabolic homeostasis ([@bib161]). A very recent study has highlighted the critical importance of cell-intrinsic metabolism in ILC2s ([@bib110]). In this study, human and murine ILC2s were shown to express arginase, and cellular bioenergetics controlled by arginine metabolism mediated ILC2 proliferation and production of type 2 cytokines and their ability to promote allergic lung inflammation in mice ([@bib110]). Together, these studies bring up fascinating questions regarding how factors in the diet and environment regulate ILC2-mediated metabolic homeostasis and how ILC2-intrinsic metabolism contributes to diverse ILC2 functions. Ultimately, integrated biochemical and immunological approaches will be needed to identify pathways that influence the balance of prohomeostatic and inflammatory ILC2 responses to support concurrent regulation of metabolism, immunity, and inflammation in mice and humans.

The emerging importance of T-bet--expressing ILCs and ILC1s {#s11}
===========================================================

The characterization of the non-NK cell ILC subset analogous to Th1 cells, the T-bet--expressing ILCs, remained elusive for several years after the identification of ILC2s and ILC3s ([@bib36]; [@bib96]; [@bib4]). Although the existence of T-bet-- and IFN-γ--expressing noncytolytic, helper-like ILC1s and their contribution to type 1 inflammation seemed likely, how ILC1s differed from classical NK cells and other ILC subsets, how these cells developed, and how they contributed to immune responses remained unclear until relatively recently. Here, we will distinguish and discuss the T-bet--expressing ILCs in two groups: T-bet--expressing ILCs that previously expressed RORγt and the T-bet--expressing ILC1s that lack a history of RORγt expression.

T-bet--expressing "ex-ILC3s" and ILC1 development and function {#s12}
--------------------------------------------------------------

An early study by [@bib171] showed that murine NCR^−^RORγt^+^ ILCs could lose RORγt expression and acquire the ability to produce IFN-γ in response to IL-12 and IL-15 and that these cells could drive colitis. In the same year, [@bib21] showed that a subset of human NCR-expressing RORγt^+^ ILC3s could acquire the ability to produce IFN-γ in response to cytokine signals. Although these studies did not measure expression of T-bet in these IFN-γ--producing ILCs ([@bib21]; [@bib171]), these data suggest that functional plasticity exists in the ILC3 lineage and that a T-bet-- and IFN-γ--expressing ILC1 population can arise from an ILC3 population. Indeed, experiments by [@bib11] described ILCs in human tonsil and intestine that expressed T-bet, responded to IL-12 to produce IFN-γ, were enriched in the intestine of patients with Crohn's disease, and could differentiate from RORγt-expressing ILC3-like cells. In addition, T-bet expression in ILC3s, associated with RORγt down-regulation, can drive acquisition of NKp46 and IFN-γ expression, mediating intestinal inflammation and homeostasis during *S. enterica* infection in mice (though these particular ILCs appear to be more ILC3-like in vivo; [@bib80]). Together, these data highlight a functionally unique niche for murine and human T-bet--expressing ILCs that previously expressed RORγt, now referred to as "ex-ILC3s" ([Fig. 3](#fig3){ref-type="fig"}).

![**ILC1s express T-bet and IFN-γ and contribute to type 1 inflammation.** T-bet--expressing ILC1s develop from a progenitor that expresses PLZF and Id2 and responds to IL-15. RORγt-expressing cells can also lose expression of RORγt and gain expression of T-bet in response to IL-12 signaling (ex-ILC3s). T-bet--expressing ILCs with a history of RORγt expression or T-bet^+^ ILC1s respond to IL-12 and IL-15 to produce IFN-γ that is protective during infection with pathogens such as *C. difficile*, *T. gondii*, and hepatitis B (not depicted: T-bet--expressing ILCs that currently or previously expressed RORγt are specifically important during infection with *S. enterica* as well, though these ILCs are more ILC3 like) and may contribute to inflammation and pathology in the intestine in the context of IBD.](JEM_20160525_Fig3){#fig3}

More recent work has more clearly defined the development and function of T-bet--expressing ILC1s that likely lack a history of RORγt expression ([Fig. 3](#fig3){ref-type="fig"}). Experiments from [@bib47] identified an intraepithelial ILC1 population in humans and mice that responded to IL-12 and IL-15 to produce IFN-γ. These cells were enriched during human and murine colitis and developed independently of RORγt in mice ([@bib47]). [@bib28] described a dedicated ILC precursor that expressed PLZF in mice and could differentiate into ILC1s, ILC2s, and ILC3s but not classical NK cells or LTi cells. Similarly, seminal work from [@bib81] defined an Id2-dependent ILC precursor in mice, the common progenitor to all helper-like ILCs (ChILP), that differentiated into ILC2s and ILC3s and gave rise to T-bet-- and IFN-γ--expressing ILC1s that protected against the intracellular protozoan parasite *Toxoplasma gondii*. A very recent study has shown that the transcription factor Runx3 controls murine ILC1 development and survival ([@bib44]). Functionally, murine ILC1s are important in mediating immunity to *T. gondii* ([@bib81]), human ILC1s are increased in patients with chronic hepatitis B infection ([@bib186]), and distinct tissue-resident ILC1-like cells are mobilized in response to cell transformation in murine models ([@bib32]). These data indicate that T-bet--expressing ILC1s that lack a history of RORγt expression are developmentally and functionally distinct ILCs that contribute to immunity to specific pathogens and tumor surveillance in both mice and humans ([Fig. 3](#fig3){ref-type="fig"}).

Evolving questions in ILC1 biology {#s13}
----------------------------------

Studies using transcription factor reporter mice, murine models of infection, and human ILCs in vitro and ex vivo have increased our understanding of ILC1 function ([@bib21]; [@bib11]; [@bib47]; [@bib28], [@bib29]; [@bib81]). However, significant questions remain. For example, the molecular nature of the connection between ILC3s and ILC1s that results in the formation of ex-ILC3s in response to environmental cues is not fully defined. Future studies using fate-mapping reporter mice to track the life history of RORγt- and T-bet--expressing ILCs in T-- and B cell--sufficient mice will be required to determine how plasticity is regulated and how it affects immune responses. Interestingly, recent work from the Immunological Genome Consortium showed that there was significant overlap in transcriptional profiles of murine ILC1-like cells as compared with classical NK cells and ILC3s ([@bib135]), and expression of eomesodermin distinguishes ILC1s and classical NK cells during development ([@bib56]; [@bib33]; [@bib81]; [@bib126]). A better understanding of the relationship between ILC1s and ILC3s will be key in deciphering the significance of T-bet--expressing cells that previously expressed RORγt in various contexts.

Although it has been assumed that ILC1s functionally resemble Th1 cells, their contribution to various inflammatory states has not been fully explored. Based on their association with Crohn's disease in humans ([@bib11]; [@bib47]), it seems likely that ILC1s are involved in the pathogenesis of IBD. In addition, as IBD is strongly associated with dysregulation of the relationship between the host and the microbiota ([@bib3]), ILC1s can likely integrate cues from the microbiota or damaged epithelial cells to modulate inflammatory responses, though whether murine or human ILC1s have this ability and its significance remain unclear. In addition to their potential role in intestinal inflammation, ILC1s likely contribute to inflammation at other tissue sites. ILC1s that express CD4 are increased in humans with systemic sclerosis ([@bib134]), and circulating IL-22 and ATP levels are increased in patients after liver resection, with ILC1s being a potent source of IL-22 in this context ([@bib84]). These data suggest that ILC1s play a role in various autoimmune and inflammatory conditions. Notably, a recent study showed that murine NKp46^+^ ILC1s in the vaginal mucosa actually dampened CD8^+^ T cell responses after local vaccination, suggesting that ILC1s could also have antiinflammatory properties ([@bib92]).

In addition, ILC1s likely contribute to immune responses to various viral, bacterial, and protozoan pathogens. Although we know that transferred T-bet--expressing ILC1s that developed from the ChILP provided protection from *T. gondii* infection in *Rag2^−/−^Il2rγ^−/−^* mice ([@bib81]), how these cells contribute to protective inflammation and immune-mediated pathology after infection with diverse pathogens, including other protozoans and intracellular bacterial pathogens, is unclear. A recent key study has highlighted the critical importance of T-bet--expressing ILC1s, with ILC3s playing a minor role, in antibacterial immune responses after infection with *Clostridium difficile* ([@bib1]), but much remains to be discovered regarding the regulation and function of these cells and T-bet--expressing ILCs with a history of RORγt expression during bacterial and, particularly, viral infection. Collectively, the studies of T-bet--expressing ILCs to date have begun to elucidate their development, lineage relationship to other ILCs, and functional capacities, but much still needs to be done to create a comprehensive phenotypic and functional profile for murine and human ILC1s.

The next challenges: Targeting ILCs in human diseases {#s14}
=====================================================

The critical roles that ILCs play in a myriad of disease states suggest that novel therapeutics that target these cells could improve outcomes for inflammatory diseases in humans ([@bib75]; [@bib96]; [@bib4]; [@bib55]; [@bib123]). The emphasis that recent studies have placed on the biology of human ILCs reflects interest in exploring this possibility. Although there are multiple disease states that could be treated by modulating ILC function, here we briefly highlight potential opportunities to therapeutically target ILC activities in two human diseases, IBD and asthma, and discuss the challenges that may be encountered in the course of developing drugs in this context.

The close association of ILC3s with intestinal inflammation has prompted long-standing interest in the role of ILC3s in IBD ([@bib96]; [@bib4]; [@bib55]). Importantly, ILC3s are enriched or their phenotypes are altered in the inflamed intestine of patients with IBD ([@bib52]; [@bib11]; [@bib47]; [@bib63]). Together with data from murine models, these studies support the idea that ILC3s might be targeted to treat IBD ([@bib55]). However, two major challenges exist when considering pursuing this approach. First, ILC3s are rich sources of IL-22, which can be protective or pathogenic in the intestine ([@bib192]; [@bib158]; [@bib69]; [@bib78]). Thus, whether changes in IL-22--producing ILC3 populations in the intestine of IBD patients are a cause or effect of intestinal inflammation remains unclear. Second, the importance of the relationships between intestinal ILC3s, the microbiota, and other immune cells ([@bib41]; [@bib164]; [@bib96]; [@bib4]) suggests that modulating ILC3 function could have off-target effects on the host--microbiota relationship, though evidence suggests that NCR-expressing ILC3 deficiency does not affect the composition of the microbiota in mice ([@bib132]). Notably, a recent study in mice has shown that transient inhibition of Rorγt in murine models of intestinal inflammation spares beneficial ILC3 function and specifically targets pathogenic Th17 responses ([@bib178]). These findings suggest that certain pathways associated with ILC3 function can be targeted without compromising the tissue-protective functions of these cells ([@bib178]) or that differences in the spacial, temporal, or functional distribution of T cells and NCR^+^ and NCR^−^ ILC3 subsets could be leveraged to develop specific therapies. Additional research in preclinical models and examining human intestinal ILC3s in healthy individuals and through a time course of disease and after treatment in IBD patients will be needed to determine whether ILC3s and their regulatory pathways are appropriate targets to treat IBD in humans.

The importance of ILC2s in allergic airway disease was first highlighted in murine models ([@bib58]; [@bib75]; [@bib96]; [@bib4]), and recent studies have revealed an association between ILC2s and asthma in humans ([@bib10]; [@bib20]; [@bib26]). Thus, ILC2s have been proposed as targets for therapeutic intervention in various asthma endotypes ([@bib75]; [@bib96]; [@bib4]; [@bib123]). Notably, recent work has shown that pro-allergic ILC2 responses are regulated by eicosanoids ([@bib9]; [@bib37]; [@bib75]; [@bib96]; [@bib4]; [@bib123]; [@bib165]), suggesting that ILC2 function could be modulated indirectly by manipulating eicosanoid pathways ([@bib125]). Specifically, as the PGD~2~--CRTH2 pathway is associated with ILC2 activation ([@bib9]; [@bib182]; [@bib165]), inhibition of this axis could be effective, and indeed, some clinical trials have shown that CRTH2 inhibition can decrease asthma symptoms, though this is not uniformly effective ([@bib125]). In addition, as LXA~4~ can limit human ILC2 responses and is decreased in patients with severe asthma, treatment with exogenous LXA~4~ or agonism of its receptor may also be a possibility ([@bib123]). In addition, recent work showing that arginase is expressed by human and murine ILC2s and mediates their function in allergic pulmonary inflammation suggests that the ILC2--arginase axis could be modulated to treat allergic asthma in humans ([@bib110]), particularly in light of previous work validating the arginine pathway as a potential therapeutic target in human disease ([@bib153]). Thus, efforts to regulate ILC2 activities to treat asthma are already underway in some respects. However, significant challenges remain. In particular, targeting ILC2s in the lung may have unwanted side effects, as these cells also mediate tissue repair ([@bib108]; [@bib168]). Second, inhibiting factors upstream of ILC2 responses may impact other cell types as well, and further work will be needed to determine whether targeting ILC2s or the factors that regulate them will be effective and safe, though recent studies showing that type 1 IFN and IL-27 limit pathogenic ILC2 functions ([@bib40]; [@bib95]; [@bib112]) suggest that we have much to learn about ILC2 regulation and that proinflammatory ILC2 activities could be limited by enhancing pathways that shut down these cells. Finally, although important studies have been performed to characterize ILC2 biology in the human lung ([@bib103]; [@bib108], [@bib110]; [@bib61]; [@bib165]; [@bib34]), how mechanistic data derived from studies of murine models of allergic respiratory disease will translate into studies of human patient populations remains unknown. Thus, studies in preclinical models that closely reflect human asthma phenotypes and endotypes and extensive characterization of ILC responses in diverse groups of asthma patients will be required to validate ILC2s as a target in asthma treatment.

The examples of IBD and asthma provide potential opportunities to modulate ILC function to treat inflammatory diseases that cause significant morbidity. The challenges that exist in this endeavor are formidable, and a common theme is the difficulty inherent in selectively targeting ILCs ([@bib96]; [@bib4]; [@bib55]; [@bib123]). However, a recent study in which ILC3 populations were unexpectedly selectively depleted in multiple sclerosis patients who were treated with an anti-CD25 antibody ([@bib124]) suggests that there are pathways that can be exploited to modulate ILCs. However, preclinical models will again be required to validate whether certain pathways that influence, but are not specific to, ILCs might be appropriate for therapeutic targeting. Preclinical models used in conjunction with genome-wide profiling may also be useful in identifying truly unique pathways that could be modulated to alter ILC responses. In addition, detailed immunological analyses of patient responses after treatment with an array of monoclonal antibodies and small molecules will be critical in identifying whether any preexisting therapies selectively regulate ILCs. Ultimately, the complex nature of the relationship between ILCs, the epithelium, the microbiota, and other immune cells suggests that altering ILC function to treat inflammatory disease will be challenging. Conversely, the placement of ILCs at the center of such a powerful immunological communication network also makes these cells a unique target in the treatment of inflammatory diseases.
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